ArticleProceedings of the National Academy of Sciences of the United States of America1991
Use of heteropolymeric monoclonal antibodies to attach antigens to the C3b receptor of human erythrocytes: a potential therapeutic treatment.
Article in Proceedings of the National Academy of Sciences of the United States of America, 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Imidazolium-based zwitterionic liquid-modified PEG-PLGA nanoparticles as a potential intravenous drug delivery carrier.Nanoscale · 2024Article
- Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers.Advanced drug delivery reviews · 2021Review
- Red Blood Cell Hitchhiking: A Novel Approach for Vascular Delivery of Nanocarriers.Annual review of biomedical engineering · 2021Article
- Cell relay-delivery improves targeting and therapeutic efficacy in tumors.Bioactive materials · 2021Article
- Red Blood Cell Membrane Processing for Biomedical Applications.Frontiers in physiology · 2019Review
- Erythrocytes as Carriers for Drug Delivery in Blood Transfusion and Beyond.Transfusion medicine reviews · 2017Review
- Red blood cells: Supercarriers for drugs, biologicals, and nanoparticles and inspiration for advanced delivery systems.Advanced drug delivery reviews · 2016Review
- Delivery of drugs bound to erythrocytes: new avenues for an old intravascular carrier.Therapeutic delivery · 2015Review
- Cell or cell membrane-based drug delivery systems.Theranostics · 2015Review
- Targeting and depletion of circulating leukocytes and cancer cells by lipophilic antibody-modified erythrocytes.Journal of controlled release : official journal of the Controlled Release Society · 2014Article
- Distearoyl anchor-painted erythrocytes with prolonged ligand retention and circulation properties in vivo.Advanced healthcare materials · 2014Article
- Drug delivery by red blood cells: vascular carriers designed by mother nature.Expert opinion on drug delivery · 2010Review
- Article
- Therapeutic applications of monoclonal antibodies.The American journal of the medical sciences · 2002Review
- Complement-independent binding of microorganisms to primate erythrocytes in vitro by cross-linked monoclonal antibodies via complement receptor 1.Infection and immunity · 1995Article
- In vivo clearance by the mononuclear phagocyte system in humans: an overview of methods and their interpretation.Clinical and experimental immunology · 1992Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
We have prepared bispecific, cross-linked monoclonal antibodies (heteropolymers) with specificity for both targeted antigens and the human erythrocyte (RBC) complement receptor. These heteropolymers facilitate binding of target antigens (human IgG and dinitrophenylated bovine gamma globulin) to human RBCs under conditions that either allow or preclude complement activation. Quantitative analyses of this binding agree well with the number of complement receptors per RBC. In vitro "whole-blood" model experiments indicate heteropolymer-facilitated binding of antigens to RBCs is rapid and stable at 37 degrees C. It may be possible to extend these prototype experiments to the in vivo situation and use heteropolymer-attached RBCs for the safe and rapid binding, neutralization, and removal from the circulation of pathogenic antigens associated with infectious disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.